1. Introduction {#sec1}
===============

In early March 2020, the World Health Organization declared the outbreak caused by the novel coronavirus disease 2019 (COVID-19) as a public health emergency of international concern ([@bib2]). Since then, our knowledge of the clinical phenotype has evolved considerably. Symptoms of COVID-19 go beyond just lung involvement to potentially affecting all organ systems ([@bib10]). More literature have reported COVID-19 impacting the neurologic system, specifically with cerebrovascular disease ([@bib2]; [@bib26]; [@bib7]). However, most reports of COVID-19's association with stroke have focused on either how our systems of care have changed ([@bib24]; [@bib11]) or are limited case series reports ([@bib2]; [@bib22]).

One proposed etiology has been an exaggerated systemic inflammation response to the virus can lead to ischemic stroke, but prior studies have been limited ([@bib27]). The neutrophil to lymphocyte ratio (NLR) is an established inflammation marker of the systemic inflammatory response and is easily calculated from routine blood work by dividing absolute neutrophil count by absolute lymphocyte count ([@bib14]; [@bib16]). Patients with more severe COVID-19 have been shown to have higher NLR, indicating an enhanced inflammatory process that might not be detected with other inflammatory markers ([@bib27]; [@bib14]; [@bib16]). Importantly, racial differences have impacted outcomes of patients with COVID-19 ([@bib23]). In this study, we describe the clinical differences, including race, between ischemic stroke patients with and without COVID-19 and laboratory findings including NLR.

2. Methods {#sec2}
==========

This is an observational, cross-sectional study of patients with confirmed acute ischemic stroke between late March to early May 2020 ​at a single-center urban academic referral hospital in the Southern United States. The hospital receives patients from multiple neighboring Southern states. Data was obtained using the center's registry of patients admitted with acute ischemic stroke. The registry received Institutional Review Boards (IRB) approval and followed the standards to protect patients' safety and privacy while gathering clinical information.

Patients (≥18 years) presenting to the center with imaging-verified ischemic stroke during the study period were identified. Electronic medical records were abstracted to confirm stroke cases, and to collect information on: Demographics (age, gender, race), clinical variables (co-existing conditions), laboratory data (complete blood count, blood chemistry, and coagulation tests at admission), and prognostic outcomes (mortality, length of hospital stay, discharge disposition). NLR served as an index of systemic inflammatory response ([@bib27]).

Upon admission, all patients in our cohort were tested for COVID-19 infection similarly to other reported protocols ([@bib2]). Testing for COVID-19 were performed in accordance with standards established by the World Health Organization using reverse-transcriptase polymerase chain reaction from nasopharyngeal swab samples. We categorized our admitted patients with stroke based on COVID-19 status (positive versus negative). Ischemic stroke patients without COVID-19 were our control population.

2.1. Statistical analysis {#sec2.1}
-------------------------

We calculated descriptive statistics using Wilcoxon two-sample test and Fisher's exact test for continuous and categorical variables, respectively. All analysis was performed using SAS version 9.4 (Cary, USA).

3. Results {#sec3}
==========

A total of 60 hospitalized patients with acute ischemic stroke were included in the analysis, of whom nine were positive for COVID-19 infection. Average age of infected patients was 58.2 ​± ​18.3 years, three were male, and five were African American. At the time of admission, they presented with a more severe neurological deficit as indicated by a higher NIHSS 18.4 ​± ​8.8 (p ​= ​0.04). Otherwise, past medical history and stroke subtypes were similar between groups. [Table 1](#tbl1){ref-type="table"} reports demographics, clinical variables, laboratory findings, and prognostic outcomes.Table 1Summary of patients with ischemic stroke.Table 1With Covid-19 (N ​= ​9)Without Covid-19 (N ​= ​51)*p*-valueDemographic CharacteristicsAge -- yr. (mean ​± ​SD)58.2 ​± ​18.365.9 ​± ​13.90.25Male (%)3 (33.3)24 (45.3)0.72Race (%) White4 (44.4)29 (58.5)0.61 African American/Black5 (55.6)20 (37.7) Other0 (0.0)2 (3.8)Medical History Hypertension (%)7 (77.8)46 (90.6)0.2664 Diabetes (%)3 (33.3)19 (35.6)1.00 Hyperlipidemia (%)2 (22.2)28 (52.8)0.15 History of stroke (%)1 (11.1)12 (22.6)0.67 Atrial Fibrillation (%)2 (22.2)13 (24.5)10,000 Smoking (%)2 (22.2)18 (33.8)0.71 Coronary Artery Disease (%)0 (0.0)6 (11.3)0.58 Congestive heart failure (%)0 (0.0)13 (24.5)0.18 Substance abuse (%)3 (33.3)5 (9.4)0.08 Chronic Kidney Disease (%)2 (22.2)6 (11.3)0.33 DVT/PTE (%)1 (11.1)8 (15.1)1.00Stroke Information NIHSS score on admission (mean ​± ​SD)18.4 ​± ​8.810.5 ​± ​8.90.04∗Ischemic stroke subtypes Large artery (%)0 (0.0)10 (18.9)0.72 Small vessel (%)1 (11.1)5 (9.4) Cardioembolism (%)2 (22.2)11 (20.8) Other (%)1 (11.1)5 (9.4) Cryptogenic (%)5 (55.6)22 (41.5)Laboratory Values (mean ​± ​SD) WBC (4-11 μL)10.8 ​± ​6.59.1 ​± ​3.00.84 Lymphocytes (15--52 ​mm^3^)14.6 ​± ​8.823.7 ​± ​10.30.01∗ Neutrophils (35--73 ​mm^3^)76.4 ​± ​11.566.8 ​± ​12.00.03∗ NLR7.3 ​± ​4.23.8 ​± ​2.80.01∗ Eosinophils (0--5 ​cells/mm^3^)2.6 ​± ​1.31.5 ​± ​1.30.04∗ Basophils (0--2 ​cells/mm^3^)0.7 ​± ​0.50.7 ​± ​0.40.85 Monocytes (4--13 ​cells/mm^3^)5.7 ​± ​3.17.5 ​± ​2.70.07 Hemoglobin (11.3--15.2 ​g/dL)10.1 ​± ​2.612.7 ​± ​2.00.01∗ Hematocrit (33--45%)30.1 ​± ​8.138.3 ​± ​5.80.007∗ Platelet (150--400 ​mm^3^)204.3 ​± ​112.2233.3 ​± ​74.80.52 Sodium (133--145 ​mEq/L)137.4 ​± ​5.7137.3 ​± ​5.00.84 Potassium (3.1--5.1 ​mEq/L)3.8 ​± ​0.44.1 ​± ​0.60.09 Bicarbonate (22--32 mEq/L)22.7 ​± ​4.324.6 ​± ​3.80.15 Magnesium (1.7--2.5 ​mg/dL)1.8 ​± ​0.32.9 ​± ​6.20.52 Chloride (97--108 mEq/L)103.6 ​± ​5.2103.6 ​± ​7.50.73 Anion Gap (4--16 mEq/L)11.2 ​± ​4.59.9 ​± ​2.80.61 Glucose (70--100 ​mg/dL)125.1 ​± ​47.7124.8 ​± ​69.50.56 Blood urea nitrogen (5--22 ​mg/dL)20.2 ​± ​11.418.1 ​± ​9.80.63 Serum creatinine (0.4--1.2 ​mg/dL)1.1 ​± ​0.61.8 ​± ​5.20.73 Low density lipoprotein (100--130 ​mg/dL)73.6 ​± ​29.399.1 ​± ​37.50.07 Hemoglobin A1C %7.2 ​± ​2.511.3 ​± ​34.80.61 Albumin (3.7--5.5 ​g/dL)2.9 ​± ​0.77.5 ​± ​16.60.008∗ Prothrombin Time (12--14.5 ​s)16.9 ​± ​3.313.9 ​± ​1.70.03∗ Activated partial thromboplastin time (25--35 ​s)40.9 ​± ​15.429.0 ​± ​5.20.004∗ INR1.4 ​± ​0.31.1 ​± ​0.20.04∗ Alkaline phosphatase (37--117 Units/L)[a](#tbl1fna){ref-type="table-fn"}^,^[b](#tbl1fnb){ref-type="table-fn"}89.0 (72.0--106.0)---- Aspartate aminotransferase (12--39 Units/L)[a](#tbl1fna){ref-type="table-fn"}^,^[b](#tbl1fnb){ref-type="table-fn"}49.0 (28.0--96.0)---- Alanine aminotransferase (7--52 Units/L)[a](#tbl1fna){ref-type="table-fn"}^,^[b](#tbl1fnb){ref-type="table-fn"}38.0 (11.0--283.0)---- Cardiac Troponin (3--15 ​ng/L)[a](#tbl1fna){ref-type="table-fn"}^,^[b](#tbl1fnb){ref-type="table-fn"}235.5 (107.0--2147.5)---- Fibrinogen (220--498 ​mg/dL)[a](#tbl1fna){ref-type="table-fn"}^,^[b](#tbl1fnb){ref-type="table-fn"}207.0 (180.0--1165.0)---- D-Dimer (0--240 ​ng/mL)[a](#tbl1fna){ref-type="table-fn"}^,^[b](#tbl1fnb){ref-type="table-fn"}2103.5 (1011.5--9973.3)---- C-reactive protein (0--10.9 ​mg/L)[a](#tbl1fna){ref-type="table-fn"}^,^[b](#tbl1fnb){ref-type="table-fn"}219.8 ​± ​52.9----Prognostic Outcomes Length of stay for discharged patients[a](#tbl1fna){ref-type="table-fn"}6.0 (4.0--14.0)3.0 (1.0--6.0)0.08Discharge disposition (%) Home1 (11.1)29 (54.7)\<0.001∗ Skilled nursing facility/subacute rehab0 (0.0)5 (9.4) Inpatient rehab0 (0.0)10 (18.9) Transfer to other hospital2 (22.2)1 (1.9) Deceased4 (44.4)4 (7.6) Still admitted2 (22.2)4 (7.6)[^1][^2][^3][^4]

3.1. Stroke severity {#sec3.1}
--------------------

Patients with NIHSS score higher than 4 also had a significantly high NLR (p ​= ​0.0069; not shown in tables). However, prothrombin time (p ​= ​0.6516) and partial thromboplastin time (p ​= ​0.8124) were not significantly different in patients with high and low NIHSS scores.

3.2. Laboratory findings {#sec3.2}
------------------------

Patients with COVID-19 had an increased inflammatory response, including higher neutrophil counts \[mean (SD) 76.4 (11.5) vs 66.8 (12.0); *P* ​= ​0.0268\], lower lymphocyte count \[14.6 (8.8) vs 23.7 (10.3); *P* ​= ​0.01\], and increased NLR compared with those patients with no infection \[7.3 (4.2) vs 3.8 (2.8); *P* ​= ​0.0137\]. [Fig. 1](#fig1){ref-type="fig"} shows an example of a patient with severe COVID-19 infection (NLR ​= ​30.3) and stroke.Fig. 1Example of patient with severe COVID-19(NLP ​= ​30.3)infection and bilateral, multifocal diffusion restriction in the (A) deep white matter structures and (B) subcortices.(C) CT Chest demonstrating large bibasilar consolidations with scattered groundclass opacities with superimposed consolidations.Fig. 1

3.3. Prognostic outcomes {#sec3.3}
------------------------

Stroke patients with COVID-19 had a significantly higher mortality rate (44.4% vs. 7.6%; p ​\< ​0.001) compared to those without COVID-19. The average length of hospital stay in discharged patients was longer for stroke patients with COVID-19 than those without, but the difference was not clinically significant.

4. Discussion {#sec4}
=============

We report important clinical and laboratory differences in ischemic stroke patients with and without COVID-19. To our knowledge, two prior studies have compared these two populations, neither of which addressed racial differences or NLR differences between groups ([@bib26]; [@bib21]). We report the first experience within the "Stroke Belt" of the Southern United States, which has the highest proportion of African-American stroke patients ([@bib9]). Our cohort had a higher proportion of African-American patients with COVID-19 and stroke than the New York cohort (55.6% vs 15.6%) ([@bib26]). This racial disparity could be due to a higher proportion of African American population in the Southeast region compared to other parts of the country. Additionally, the New York cohort did not report their number of African-Americans with stroke who did not have COVID. In our cohort, COVID-19 patients with stroke demonstrated higher severity of neurologic deficit (NIHSS) and a higher mortality rate. These findings were comparable with the New York study which reported a higher median \[IQR\] NIHSS score: (19 \[23\] vs 8 \[12\], *P* ​= ​0.007) and inpatient mortality (63.6% versus 9.3%, *P* ​\< ​0.001) among stroke patients with COVID than without ([@bib26]). Similarly, Ntaios et al. also reported a significantly higher median NIHSS (10 \[4--18\] vs 6 \[3--14\], P ​= ​0.003) and higher mortality (OR ​= ​4.3 \[95% CI, 2.22--8.30\] among stroke patients with COVID-19 versus without ([@bib21]).

The Southern United States has disproportionately higher rates of stroke mortality than the rest of the country ([@bib9]). As COVID-19 has disproportionately burdened African-American communities ([@bib12]), disparities are likely to widen with other medical conditions ([@bib20]) as well that disproportionately affect this community, such as stroke ([@bib3]). Additionally, experiences with racial discrimination were associated with elevated cytokine levels in certain African-American groups ([@bib6]). These findings offer an important opportunity to focus education and public health resources on vulnerable populations.

Some studies have suggested the coagulopathy from COVID-19 is caused by a precursor state to disseminated intravascular coagulation ([@bib5]). In our study, we had a small but significant increase in coagulation factors in COVID-19 positive stroke patients compared to those without COVID-19. However, coagulation factors were not independently associated with stroke severity in our study. In contrast, we saw a significantly higher NLR in COVID-19 patients. NLR is a well-studied serum biomarker for systemic inflammation in COVID-19 ([@bib27]; [@bib16]; [@bib15]). The components of the NLR are routinely collected in clinical practice, unlike other systemic inflammatory markers like C-reactive protein and cytokine levels ([@bib14]). As part of the complete blood count with differential, the neutrophil count and the lymphocyte count, are already obtained and the ratio can be easily calculated. This would make NLR a cost-effective marker in helping assess disease severity and predict complications ([@bib14]).

Interestingly, in our patients with stroke and COVID-19, the neutrophil and lymphocyte levels were only borderline high and low, respectively. Yet, the NLR was almost twice as high as patients without COVID-19. This potentially indicates that the systemic inflammatory response triggered by COVID-19 can cascade from multiple components. *Yang* et al. found that a NLR above the optimum cut-off (3.3) was an independent prognostic biomarker that affected pneumonia progression in COVID-19 patients ([@bib27]). Notably, mean NLR was 7.3 in our study. Increased NLR has also been associated with COVID-19 disease severity, refractory disease, and even an independent factor for mortality ([@bib16]). Our study is the first study to associate the NLR in patients with COVID-19 and ischemic stroke and stroke severity.

COVID-19 infection likely triggers an exaggerated inflammatory response leading to an excessive production of cytokines or "cytokine storm." ([@bib5]; [@bib18]) Neutrophils triggered by viral-related cytokines cause tissue damage by release of reactive oxygen species, and inhibit the cytotoxic T-cell response needed to fight viral infection ([@bib27]). Proinflammatory cytokines are known to be increased in COVID-19 patients and associated with disease severity ([@bib5]; [@bib19]). Subsequent vascular leakage and interstitial edema damage tissues including myocardium and blood vessels ([@bib18]). A recent study found T-cells were reduced in COVID-19 patients requiring critical care, and these reductions were associated with higher cytokine levels. The authors suggested T-cells were initially hyperactivated and subsequently exhausted in the infection process, impairing anti-viral immunity ([@bib4]). Perhaps the lower circulating lymphocyte counts in our COVID-19 patient cohort was due to reduced T-cells. T-cell lymphocytes are needed to dampen an overactive innate immune response, and subsequent increase of these lymphocytes are seen in disease recovery ([@bib19]). Prior studies of COVID-19 patients found increased neutrophils are associated with a higher risk of acute respiratory distress syndrome, while lymphopenia has been associated with worse outcomes, increased need for critical care, and increased mortality ([@bib25]). Medications that can block the systemic inflammatory response such as Dexamethasone, a corticosteroid, have had early reports that suggest improved outcomes due to its ability to suppress neutrophils ([@bib8]). African-Americans have known genetic variations associated with inflammation measured using the NLR and increased risk of cardiovascular disease and stroke ([@bib1]; [@bib13]). In these populations who receive medications like dexamethasone, it will be important to monitor the differences in their medications effects.

Our study has several limitations. First, this was a retrospective, observational single-center study with a small sample size, which limited our ability to perform multivariable statistical analysis. Secondly, even though overall our cohort had a large proportion of African American population, within the COVID-19 group, the absolute difference in the numbers of African American patients versus other race was one. Therefore, the results of this report should be interpreted with caution. Third, not all patients had the same completeness of laboratory data and so some comparisons could not be made. Fourth, we do not have all prognostic outcomes since some patients were still admitted and receiving clinical care. Finally, we did not study hemorrhagic stroke, which warrants further investigation.

5. Conclusion {#sec5}
=============

We observed a cohort of patients including a large proportion of African-American population, who developed ischemic stroke with or without COVID-19. Those with COVID-19 and ischemic stroke had higher stroke severity and increased mortality. We also found that an increased NLR among stroke patients with COVID-19 indicates a more severe systemic inflammatory response that impacts clinical characteristics and warrants further investigation.
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[^1]: ∗ p-values\<0.05.

[^2]: Standard deviation (SD), Deep vein thrombosis (DVT), Pulmonary thromboembolism (PTE), The National Institutes of Health Stroke Scale (NIHSS), White blood cells (WBC), Neutrophil-to-lymphocyte ratio (NLR), International normalized ratio (INR).

[^3]: Values reported as Median (Interquartile range).

[^4]: Values for stroke patients without Covid-19 not reported due to missing values for more than 20% patients.
